Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Investor Presentation (July 2024)
43 slides from Piramal Pharma's investor presentation, July 2024
Slide 1: Investor Presentation July 2024
Investor Presentation July 2024
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Piramal Pharma - Phases of our Evolution
Piramal Pharma - Phases of our Evolution 1988 2010 2020 2022 Piramal Healthcare Piramal Enterprises Ltd. Piramal Pharma Ltd. Domestic Formulations CDMO Piramal Pharma Financial Services Pharma Solutions (CDMO) Complex Hospital Generics (CHG) Nicholas CDMO Wholesale Lending Laboratories Critical Care
Slide 4: Piramal Pharma - Demerged and Listed on BSE and NSE
Piramal Pharma - Demerged and Listed on BSE and NSE Demerger and Simplification of Corporate Structure Aligned interests of customers, patients, employees, investors, lenders and creditors Dedicated Board and management teams Independence in pursuing growth with core experiences plans, organically a
Slide 5: Three-Pronged Business Model with Global Operations
Three-Pronged Business Model with Global Operations … CDMO CHG ICH 15 CDMO sites across North America, UK/Europe and India Inhalation Anesthesia Anesthesia and Ahmedabad1 Pithampur Pain Management Grangemouth Aurora Turbhe Morpeth Mahad Rabale Digwal Riverview Sellersville Hyderabad2 Ennore Intrathe
Slide 6: …in Attractive and Large Industry Segments
…in Attractive and Large Industry Segments CDMO CHG ICH CDMO Market Growing at a …With Robust Growth in Small Healthy Pace… Molecule CDMOs Addressable market size of CHG Addressable market size of ICH (In US$ Bn) (In US$ Bn)1 CAGR of 7% CAGR of 11% 169 113 115 61 ~US$ ~US$ 47 Bn 7 Bn 2020 2026E 2020
Slide 7: Levers for Sustainable Value Creation
Levers for Sustainable Value Creation 1 2 3 4 5 6 Global Footprint Balanced Track Record of Institutional Focus on Patient Highly with a Manufacturing Inorganic and Focus on and Customer Experienced Diversified Footprint with Organic Sustainability Centricity: Management Revenue Base Best-in-Class E
Slide 8: Global Footprint with a Diversified Revenue Base
Global Footprint with a Diversified Revenue Base 17 100+ ~500 6,000+ ~180K Countries with Manufacturing and commercial Countries with presence CDMO Customers CHG Customers ICH Customers Development Commercial (Hospitals) (Chemists and Sites* Presence cosmetics shops) Revenue by Geography Revenue by
Slide 9: Diversified Global Footprint…
Diversified Global Footprint… 17 Manufacturing & Development Facilities* Across North America, UK/Europe and India 17 Manufacturing & Development Facilities Across North America, United Kingdom and India 5 2 10 Dahej Ahmedabad1 Pithampur Grangemouth Rabale Turbhe Mahad Digwal Aurora Morpeth Hyderaba
Slide 10: …with Best-in-Class Quality Track Record
…with Best-in-Class Quality Track Record 44 ~150 341 USFDA total regulatory inspections Zero annual inspections1 OAIs1,2 customer successfully audits1 cleared1 Over the last 18 months, five of our CDMO facilities at Digwal, Pithampur, Riverview, Lexington and Sellersville, contributing over ✓ half o
Slide 11: Track Record of Organic and Inorganic Expansion
Track Record of Organic and Inorganic Expansion ✓ Growth capex across Discovery, Development and Commercial Manufacturing within CDMO Healthy ROI on Organic Investments ✓ Investments to bolster capacity across key Inhalation Anesthesia products in CHG ✓ Sales Promotion to drive consumer acquisition
Slide 12: Key Sustainability Highlights for FY2024
Key Sustainability Highlights for FY2024 Climate Change Climate ChangeManagement Management Taken a target for 42% reduction in our Scope 1 and Scope 2 GHG emissions by FY30 (baseline of FY22). This is in-line with the SBTI’s# pathway to limit global warming to 1.5°C above pre-industrial levels Also
Slide 13: Key Sustainability Highlights for FY2024
Key Sustainability Highlights for FY2024 Committed to SBTi Climate Change and Community Development Diversity & Inclusion Third Party Assessment Water Security Disclosures ET Now’s Best Organization For Woman 2024 Women in global workforce Addresses complex Score 55 - Significant demographic, geogra
Slide 14: Focus on Patient and Customer Centricity: Source of Differentiation
Focus on Patient and Customer Centricity: Source of Differentiation Focusing on Patient-centricity and Customer-centricity drives our organization to provide flexible high-quality service ✓ while aligning us with our customer partners on our shared goal of serving patients ⚫ Expanding access of self
Slide 15: Highly Experienced Management Team
Highly Experienced Management Team Strategic Group Business Leadership Team Leadership Herve Berdou Stuart Needleman Jeffrey Hampton Nitish Bajaj COO – CDMO CCO – CDMO President & COO – CEO – ICH CHG Nandini Piramal Chairperson Corporate Functions Peter DeYoung CEO, Global Pharma Vivek Valsaraj Rash
Slide 16: Demonstrating Execution Against Key Strategic Priorities
Demonstrating Execution Against Key Strategic Priorities Strategic Priorities Execution ▪ Expansion of CDMO facilities - Aurora, Riverview, Grangemouth, Turbhe and Ahmedabad - witnessing high demand Continued ▪ Investment in capacity expansion at Digwal and Dahej to meet the growing demand for Inhal
Slide 17: CDMO
Piramal Pharma Limited
Slide 18: CDMO Business at a Glance
CDMO Business at a Glance CDMO 1 2 3 4 5 6 7 8 Service Deep Pipeline Diversified Attracting Expansion of Leveraging our Track Record Clearly Offerings of Development Blue Chip Customers Major Sites End-to-end of Consistent Identified Across the Projects across Customer with our through Model to offe
Slide 19: Pure Play CDMOs
Broad Archetypes of CDMO Companies CDMO CHG ICH Archetype Description What have players done to win • Consistent investment over the years to develop capabilities across End-to-end value chain coverage value chain Integrated during the lifecycle of molecule (e.g., • ‘Strategic partnership discussion
Slide 20: Service Offerings Across the Lifecycle of the Molecule
Service Offerings Across the Lifecycle of the Molecule CDMO CHG ICH >90% 139 40+ 70+ Pipeline Of Molecules Across APIs Across Therapeutic FDFs Across Therapeutic Business From Repeat Clients Phases 1,2 And 3 Areas Area and Dosage Forms Discovery Development Commercial Manufacturing 95% 34% 34% Abili
Slide 21: Deep Pipeline of Development Projects across Multiple Phases
Deep Pipeline of Development Projects across Multiple Phases CDMO CHG ICH Revenue by Services Deep Development Pipeline Across Clinical Phases (% FY24 CDMO revemue) Pre- clinical, 12% Pre-Clinical Phase I Phase II Phase III 4% Phase III, 50% 34% Innovation 26% related Development 2.9x 151 work 20% R
Slide 22: Diversified Blue Chip Customer Base
Diversified Blue Chip Customer Base CDMO CHG ICH We have an Attractive Customer Mix… … with Relatively Low Revenue Concentration ( % of FY24 CDMO Revenue) ( % of FY24 CDMO Revenue) #1 Generics 11% #2 29% Big 8% Pharma 38% 64% of revenue #3 Over 500 from Big 5% Others customers Pharma, and 54% #4 acr
Slide 23: Growth in Revenue and Contribution from Differentiated Offerings
Growth in Revenue and Contribution from Differentiated Offerings CDMO CHG ICH Revenue (US$ Mn) from Contribution of Differentiated Differentiated Offerings Offerings to CDMO Revenue High Potent API (HPAPI) Differentiated Hormonals 44% Offerings 253 Antibody Drug Peptides Conjugates (ADC) 27% On-pate
Slide 24: Leveraging Global Network of Sites to Offer Integrated Services
Leveraging Global Network of Sites to Offer Integrated Services CDMO CHG ICH Benefits of the Integrated Platform • Integrated project involves more than one site Integrated projects executed since Integrated Projects 125+ inception in 2020 • Built a platform for Integrated Service offerings through:
Slide 25: Brownfield Expansions
Brownfield Expansions CDMO CHG ICH Balanced Manufacturing Footprint with Capability to meet a Wide-range of Customer Geographic Requirements North America United Kingdom/Europe India 4 2 9 15 Global Ahmedabad1 Facilities Pithampur Grangemouth Rabale Morpeth Turbhe Mahad Aurora Digwal Riverview Selle
Slide 26: Growth Drivers for CDMO Business
Growth Drivers for CDMO Business CDMO CHG ICH Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Capacity Capability Customer Pursue inorganic growth • Increase capacity through • Increase revenue share and • Partner with customers as 35+ • Focus on expanding operational excellence attr
Slide 27: Complex Hospital Generics
Piramal Pharma Limited Complex Hospital Generics
Slide 28: CHG Business at a Glance
CHG Business at a Glance CHG 1 2 3 4 5 Differentiated Strong Pipeline in Vertically Integrated Well Built Out Clearly Identified Portfolio for Gaining Niche Areas with Manufacturing Commercial Levers of Growth Market Share and Unique Characteristics Capabilities and Infrastructure Driving Growth 27
Slide 29: Differentiated Portfolio - Gaining Market Share and Driving Growth
Differentiated Portfolio - Gaining Market Share and Driving Growth CDMO CHG ICH Revenue by Product Segment Revenue by Geography (% FY24 CHG Revenue) (% FY24 CHG Revenue) Others Other Generic and 23% 8% Injectable Anesthesia Specialty Products and pain management 10% US 51% India 15% 6% 67% Inhalatio
Slide 30: Consolidating our Position Amongst Top 4 Inhalation Anesthesia Players
Consolidating our Position Amongst Top 4 Inhalation Anesthesia Players in the World CDMO CHG ICH Global Inhalation Anesthesia Market Global IA market comprising of Sevoflurane, Isoflurane and Desflurane is about $1.04bn* China (27% market share) and US (22%) is about 50% of the above global IA marke
Slide 31: Strong Pipeline in Niche Areas with Unique Characteristics
Strong Pipeline in Niche Areas with Unique Characteristics CDMO CHG ICH Building pipeline in niche areas… …by leveraging internal capabilities and key partnerships Injectable Anesthesia Pain Management Development and manufacturing partners around the globe ✓ A broad range of other Our internal regu
Slide 32: Blend of Direct Commercialization Capabilities and Local Partners
Blend of Direct Commercialization Capabilities and Local Partners CDMO CHG ICH Marketing worldwide through a global sales and distribution network Established channel relationships and robust commercial infrastructure Direct sales force in the US with strong GPO relationships Direct to market access
Slide 33: Growth Drivers for CHG Business
Growth Drivers for CHG Business CDMO CHG ICH Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Strong pipeline Differentiated portfolio Vertical integration Business acquisitions • Developing and commercializing • Leveraging our differentiated • Continuing vertical integration for • Ca
Slide 34: India Consumer Healthcare
Piramal Pharma Limited India Consumer Healthcare
Slide 35: ICH Business at a Glance
ICH Business at a Glance ICH 1 2 3 4 5 Focus on Power Launching Multiple New Well Established Track Record of Clearly Identified Brands with Continuous Products and Brand Commercial High Growth Levers of Growth Investments in Brand Extensions Infrastructure with Promotion and Multi-channel Marketing
Slide 36: Diversified Portfolio of Attractive Brands, Including Power Brands
Diversified Portfolio of Attractive Brands, Including Power Brands CDMO CHG ICH Analgesics Skin care VMS Women’s health Digestives Kids wellness Health & Hygiene Lacto Calamine Littles Lotions, Facewash, Supradyn® i-pill Saridon® Polycrol Wipes, Toys, NIXIT Sunscreen Wipes, Multivitamin Contraceptiv
Slide 37: Focus on Power Brands - Investments in Brand Promotion and Marketing
Focus on Power Brands - Investments in Brand Promotion and Marketing CDMO CHG ICH Investments in Brand Promotion and Marketing… Kareena Kapoor Priyanka Mohan Jisshu Sengupta Amyra Dastur Ajay Devgan i-pill daily Little’s Lacto - South India Polycrol Lacto - HSM belt Tetmosol New Media launch …Reflec
Slide 38: New Product Launches – An Important Driver of Growth
New Product Launches – An Important Driver of Growth CDMO CHG ICH Regular new product launches contributing to growth CIR (Adult Hygiene Range) Recently launched Bohem New product and SKUs launches received encouraging response in (Men Grooming Range) - Hair 63 removal spray, a beard growth the firs
Slide 39: Multi-channel Distribution Network and Tech-enabled Sales Coverage
Multi-channel Distribution Network and Tech-enabled Sales Coverage CDMO CHG ICH Presence across traditional and alternate trade channels Wide coverage across Expanding presence on general trade and chemist E-Commerce Presence in ~180K Presence on over 20 chemists and leading e-commerce cosmetics sho
Slide 40: PPL Key Strategic Priorities
PPL Key Strategic Priorities 1 Drive demand in CDMO business by increasing the proposal velocity and win rate 2 Delivering consistent revenue growth and improving profitability Track record of building scalable 3 Pursuing organic and inorganic growth opportunities leveraging fresh capital differenti
Slide 41: JV with Abbvie
Piramal Pharma Limited JV with Abbvie
Slide 42: Abbvie Therapeutics India Private Limited
Abbvie Therapeutics India Private Limited* Joint Venture Arrangement Ownership Ownership 49% 51% In FY2024, the JV reported# revenue of ₹ 461Cr with PAT margin of 26% Continue to be one of 400+ Strong presence in Key Brands the market leaders in employees including glaucoma, dry eye, Refresh, Ozurde
Slide 43: For Investor Queries
For Investor Queries: Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Madhusudan Dalmia Investor Relations Email: madhusudan.dalmia@piramal.com